Skip to main content

Table 3 Prevalence of comorbidities in patients tested for SARS-CoV-2

From: Outpatient Management of Oligosymptomatic Patients with respiratory infection in the era of SARS-CoV-2: Experience from rural German general practitioners

Tested positive Tested negative
Diabetes: n = 2 (40.00%) Diabetes: n = 2 (2.67%)
Arterial hypertension: n = 3 (60.00%) Arterial hypertension: n = 23 (30.67%)
Hypothyroidism: n = 0 (0%) Hypothyroidism: n = 11 (14.67%)
Immunosuppression: n = 1 (20.00%) Immunosuppression: n = 6 (8.00%)
Atrial fibrillation: n = 1 (20.00%) Atrial fibrillation: n = 5 (6.67%)
Coronary artery disease: n = 0 (0%) Coronary artery disease: n = 3 (4.00%)
Lung disease: n = 2 (40.00%) Lung disease: n = 10 (13.33%)
Depression: n = 1 (20.00%) Depression: n = 11 (14.67%)
Chronic kidney disease: n = 0 (0%) Chronic kidney disease: n = 2 (2.67%)
RAAS inhibitors: n = 2 (40.00%) RAAS inhibitors: n = 15 (20.00%)
Oral anticoagulation: n = 1 (20.00%) Oral anticoagulation: n = 5 (6.67%)
Platelet inhibitors: n = 1 (20.00%) Platelet inhibitors: n = 1 (1.33%)